Eosinophilic Pneumonia Induced by Medications: An Analysis of Real-World Data from FAERS and Vigibase Identifying Safety Signals and Risk Trends - Top-Institutions - MDSpire

Eosinophilic Pneumonia Induced by Medications: An Analysis of Real-World Data from FAERS and Vigibase Identifying Safety Signals and Risk Trends

  • By

  • Jing Hu

  • Yao Sun

  • Cong Cheng

  • Sisi Wang

  • Xiangrong Zuo

  • Yun Liu

  • April 22, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Pulmonology
    • Interstitial Lung Disease
    • Clinical Pharmacology

  • #2

    National Jewish Health
    National Jewish Health

    Denver, CO

    Key Differentiators

    • Pulmonology
    • Allergy and Immunology
    • Pharmacovigilance

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Pulmonology
    • Pharmacology
    • Clinical Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Pulmonology
    • Clinical Pharmacology
    • Pharmacovigilance

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Pulmonology
    • Clinical Pharmacology
    • Pharmacovigilance

Original Source(s)

Eosinophilic Pneumonia Induced by Medications: An Analysis of Real-World Data from FAERS and Vigibase Identifying Safety Signals and Risk Trends

  • by Jing Hu, Yao Sun, Cong Cheng, Sisi Wang, Xiangrong Zuo, Yun Liu

  • April 22, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Case Report: Beyond conventional diagnostics: mNGS support in a complex immunocompromised patient diagnosis

Viral, Fungal Infections May Contribute to Nonresolving ARDS

Review links viral and fungal infections to persistent lung injury in nonresolving ARDS